Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 May 1;209(9):1067-1068.
doi: 10.1164/rccm.202401-0246ED.

Enrichment Strategies for Systemic Sclerosis-Interstitial Lung Disease Trials

Elizabeth R Volkmann  1 , Donald P Tashkin  1
Affiliations
Editorial

Enrichment Strategies for Systemic Sclerosis-Interstitial Lung Disease Trials

Elizabeth R Volkmann et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

References

    1. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Scleroderma Lung Study Research Group Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med . 2006;354:2655–2666. - PubMed
    1. Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. SENSCIS Trial Investigators Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med . 2019;380:2518–2528. - PubMed
    1. Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, et al. focuSSced investigators Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med . 2020;8:963–974. - PubMed
    1. Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Sclerodema Lung Study II Investigators Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med . 2016;4:708–719. - PMC - PubMed
    1. Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med . 2022;205:e18–e47. - PMC - PubMed

Publication types